Prime Medicine (PRME) Competitors $5.32 +0.20 (+3.91%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PRME vs. XENE, MOR, VKTX, CGON, HCM, OGN, RARE, KNSA, GMTX, and ALVOShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Viking Therapeutics (VKTX), CG Oncology (CGON), HUTCHMED (HCM), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Xenon Pharmaceuticals MorphoSys Viking Therapeutics CG Oncology HUTCHMED Organon & Co. Ultragenyx Pharmaceutical Kiniksa Pharmaceuticals International Gemini Therapeutics Alvotech Prime Medicine (NASDAQ:PRME) and Xenon Pharmaceuticals (NASDAQ:XENE) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Do insiders & institutionals believe in PRME or XENE? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, PRME or XENE? Prime Medicine has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$2.98M240.24-$195.88M-$1.56-3.41Xenon Pharmaceuticals$9.43M319.40-$234.33M-$3.55-11.00 Does the media favor PRME or XENE? In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Xenon Pharmaceuticals and 4 mentions for Prime Medicine. Xenon Pharmaceuticals' average media sentiment score of 1.31 beat Prime Medicine's score of 0.29 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, PRME or XENE? Prime Medicine has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Is PRME or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Xenon Pharmaceuticals' return on equity of -38.50% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime Medicine-4,016.83% -156.16% -64.41% Xenon Pharmaceuticals N/A -38.50%-36.47% Do analysts rate PRME or XENE? Xenon Pharmaceuticals has a consensus price target of $53.30, suggesting a potential upside of 36.46%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryXenon Pharmaceuticals beats Prime Medicine on 11 of the 16 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$715.91M$284.00M$2.52B$10.42BDividend YieldN/AN/A2.51%4.69%P/E Ratio-3.41N/A26.6526.39Price / Sales240.24240.24101.30125.20Price / CashN/AN/A47.3130.68Price / Book4.552.8336.316.40Net Income-$195.88M-$111.70M$12.55M$276.69M7 Day Performance6.61%20.02%-0.51%-0.28%1 Month PerformanceN/A-11.96%3.11%6.69%1 Year PerformanceN/A181.31%71.95%27.61% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine0.3333 of 5 stars$5.32+3.9%N/AN/A$689.02M$2.98M0.00N/AXENEXenon Pharmaceuticals2.486 of 5 stars$37.31-0.1%$53.30+42.9%-1.7%$2.88B$9.43M-10.51210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730VKTXViking Therapeutics4.2075 of 5 stars$24.97-4.9%$90.38+262.0%-58.5%$2.81BN/A-16.3220Analyst ForecastCGONCG Oncology2.4926 of 5 stars$36.70-0.9%$56.00+52.6%-0.9%$2.80B$1.14M-20.7361Analyst ForecastGap UpHCMHUTCHMED2.9335 of 5 stars$15.99-4.0%$20.88+30.6%-17.9%$2.79B$630.20M0.001,811OGNOrganon & Co.4.6291 of 5 stars$10.570.0%$17.33+64.1%-46.8%$2.75B$6.40B3.934,000Positive NewsRAREUltragenyx Pharmaceutical4.3148 of 5 stars$28.40-3.6%$81.50+187.0%-46.6%$2.74B$560.23M-5.141,294Positive NewsKNSAKiniksa Pharmaceuticals International2.8389 of 5 stars$36.33+0.7%$41.17+13.3%+46.0%$2.69B$423.24M908.48220Positive NewsAnalyst ForecastGap UpGMTXGemini TherapeuticsN/A$61.50+1.2%N/A+30.9%$2.66BN/A-61.5030News CoverageALVOAlvotech3.7068 of 5 stars$8.70+8.6%$14.00+60.9%-29.9%$2.62B$491.98M37.831,032High Trading Volume Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors MorphoSys Competitors Viking Therapeutics Competitors CG Oncology Competitors HUTCHMED Competitors Organon & Co. Competitors Ultragenyx Pharmaceutical Competitors Kiniksa Pharmaceuticals International Competitors Gemini Therapeutics Competitors Alvotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRME) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
